Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer
- PMID: 20200438
- PMCID: PMC2872124
- DOI: 10.1158/1055-9965.EPI-09-1112
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer
Abstract
Approximately 5% to 15% of all colorectal cancers (CRC) have an activating BRAF somatic mutation, which may be associated with a distinct risk profile compared with tumors without BRAF mutations. Here, we measured the prevalence and epidemiologic correlates of the BRAF V600E somatic mutation in cases collected as a part of a population-based case-control study of CRC in northern Israel. The prevalence of BRAF V600E was 5.0% in this population, and the mutation was more likely to be found in tumors from cases who were of Ashkenazi Jewish descent [odds ratio (OR), 1.87; 95% confidence interval (95% CI), 1.01-3.47], female (OR, 1.97; P = 1.17-3.31), and older (73.8 years versus 70.3 years; P < 0.001). These results were similar when restricting to only tumors with microsatellite instability. Whether smoking was associated with a BRAF somatic mutation depended on gender. Although men were less likely to have a tumor with a BRAF somatic mutation, men who smoked were much more likely to have a tumor with a somatic BRAF mutation (OR(interaction), 4.95; 95% CI, 1.18-20.83) than women who never smoked. We note the strong heterogeneity in the reported prevalence of the BRAF V600E mutation in studies of different ethnicities, with a lower prevalence in Israel than other Western populations but a higher prevalence among Jewish than non-Jewish Israeli cases. Epidemiologic studies of CRC should incorporate somatic characteristics to fully appreciate risk factors for this disease.
Figures
Similar articles
-
Somatic BRAF-V600E mutations in familial colorectal cancer.Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2270-3. doi: 10.1158/1055-9965.EPI-06-0359. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 17119056
-
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1774-80. doi: 10.1158/1055-9965.EPI-08-0091. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18628431
-
Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1831-9. doi: 10.1158/1055-9965.EPI-10-0055. Epub 2010 Jun 22. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20570909
-
BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.Dis Colon Rectum. 2012 Feb;55(2):128-33. doi: 10.1097/DCR.0b013e31823c08b3. Dis Colon Rectum. 2012. PMID: 22228154
-
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555. Int J Cancer. 2011. PMID: 20635392
Cited by
-
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.Am J Gastroenterol. 2014 Aug;109(8):1205-14. doi: 10.1038/ajg.2014.153. Epub 2014 Jun 17. Am J Gastroenterol. 2014. PMID: 24935274 Free PMC article. Review.
-
Genetic and epigenetic events generate multiple pathways in colorectal cancer progression.Patholog Res Int. 2012;2012:509348. doi: 10.1155/2012/509348. Epub 2012 Jul 24. Patholog Res Int. 2012. PMID: 22888469 Free PMC article.
-
Clearing the air on smoking and colorectal cancer.J Natl Cancer Inst. 2010 Jul 21;102(14):996-7. doi: 10.1093/jnci/djq241. Epub 2010 Jun 29. J Natl Cancer Inst. 2010. PMID: 20587791 Free PMC article. No abstract available.
-
MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.Eur J Hum Genet. 2012 Jul;20(7):762-8. doi: 10.1038/ejhg.2011.277. Epub 2012 Jan 25. Eur J Hum Genet. 2012. PMID: 22274583 Free PMC article.
-
The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer.Cancers (Basel). 2019 Jul 20;11(7):1017. doi: 10.3390/cancers11071017. Cancers (Basel). 2019. PMID: 31330830 Free PMC article. Review.
References
-
- Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360:1381–1391. - PubMed
-
- Farrington SM, McKinley AJ, Carothers AD, et al. Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int J Cancer. 2002;98:844–850. - PubMed
-
- Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119:921–928. - PubMed
-
- Jernvall P, Makinen MJ, Karttunen TJ, Makela J, Vihko P. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers [see comments] Eur J Cancer. 1999;35:197–201. - PubMed
-
- Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int. 2008;58:104–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA046592/CA/NCI NIH HHS/United States
- R01 CA081488-08/CA/NCI NIH HHS/United States
- L30 CA130678/CA/NCI NIH HHS/United States
- F32 CA110622/CA/NCI NIH HHS/United States
- F32 CA110622-02/CA/NCI NIH HHS/United States
- R01 CA081488/CA/NCI NIH HHS/United States
- R01 CA81488/CA/NCI NIH HHS/United States
- P30 CA046592-19/CA/NCI NIH HHS/United States
- F32 CA110622-01A1/CA/NCI NIH HHS/United States
- F32 CA110622-03/CA/NCI NIH HHS/United States
- L30 CA130678-01/CA/NCI NIH HHS/United States
- R01 CA081488-09/CA/NCI NIH HHS/United States
- CA110622/CA/NCI NIH HHS/United States
- R01 CA081488-10/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials